Clinical application of estimating hepatitis b virus quasispecies complexity by massive sequencing: Correlation between natural evolution and on-treatment evolution

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Homs, Maria ^a,b   Caballero, Andrea ^b   Gregori, Josep ^a,c   Tabernero, David ^a,b   Quer, Josep ^a,c   Nieto, Leonardo ^b   Esteban, Rafael ^a,b   Buti, Maria ^a,b   Rodriguez Frias, Francisco ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; HEPATITIS B(E) ANTIGEN; NUCLEOTIDE; VIRUS DNA;

ARTICLE; BIOLOGICAL FUNCTIONS; CONTROLLED STUDY; DNA SEQUENCE; ENTROPY; GENE IDENTIFICATION; GENE MUTATION; HEPATITIS B VIRUS; HUMAN; LONGITUDINAL STUDY; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGANISMS BY GEOGRAPHICAL DISTRIBUTION; PRESSURE MEASUREMENT; PYROSEQUENCING; QUASISPECIES COMPLEXITY; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; VIRUS IDENTIFICATION; VIRUS REPLICATION; ADULT; AGED; CHEMISTRY; CLASSIFICATION; FEMALE; GENETICS; HEPATITIS B; HIGH THROUGHPUT SEQUENCING; MALE; MIDDLE AGED; MUTATION; PROCEDURES; REPRODUCIBILITY; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS B VIRUS;

ADULT; AGED; DNA, VIRAL; EVOLUTION, MOLECULAR; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84911893455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112306     Document Type: Article

References (33)

1. WHO Hepatitis B (2014) Available at http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 29 August 2014
2. Iloeje UH, Yang H-I, Su J, Jen C-L, You S-L, et al. (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130: 678-686. Available: http://www.ncbi.nlm.nih.gov/pubmed/16530509. Accessed 29 August 2014
3. Rodriguez-Frias F, Buti M, Tabernero D, Homs M (2013) Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach. World J Gastroenterol 19: 6995-7023. Available: http://www.pubmedcentral. nih.gov/articlerender.fcgi?artid=3819535&tool=pmcentrez&rendertype=abstract. Accessed 3 April 2014
4. Kidd-Ljunggren K, Miyakawa Y, Kidd AH (2002) Genetic variability in hepatitis B viruses. J Gen Virol 83: 1267-1280. Available: http://www.ncbi.nlm.nih.gov/pubmed/12029141
5. Tedder RS, Bissett SL, Myers R, Ijaz S (2013) The ''Red Queen'' dilemma-running to stay in the same place: reflections on the evolutionary vector of HBV in humans. Antivir Ther 18: 489-496. Available: http://www.ncbi.nlm.nih.gov/pubmed/23792884. Accessed 29 August 2014
6. Noguchi C, Ishino H, Tsuge M, Fujimoto Y, Imamura M, et al. (2005) G to A hypermutation of hepatitis B virus. Hepatology 41: 626-633. Available: http://www.ncbi.nlm.nih.gov/pubmed/15726649. Accessed 18 December 2012
7. Domingo E, Holland JJ (1997) RNA virus mutations and fitness for survival. Annu Rev Microbiol 51: 151-178. Available: http://www.ncbi.nlm.nih.gov/pubmed/9343347
8. Homs M, Buti M, Tabernero D, Quer J, Sanchez A, et al. (2012) Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencing. World J Gastroenterol 18: 6096-6105. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3496886&tool=pmcentrez&render type=abstract. Accessed 29 August 2014
9. Lim SG, Cheng Y, Guindon S, Seet BL, Lee LY, et al. (2007) Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology 133: 951-958. Available: http://www.ncbi.nlm.nih.gov/pubmed/17854598. Accessed 29 August 2014
10. Cabot B, Martell M, Esteban JI, Sauleda S, Otero T, et al. (2000) Nucleotide and amino acid complexity of hepatitis C virus quasispecies in serum and liver. J Virol 74: 805-811. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=111600&tool=pmcentrez&rendertype=abstract. Accessed 29 August 2014
11. Nasu A, Marusawa H, Ueda Y, Nishijima N, Takahashi K, et al. (2011) Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS One 6: e24907. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3178558&tool=pmcentrez& rendertype=abstract. Accessed 29 August 2014
12. Cheng Y, Guindon S, Rodrigo A, Wee LY, Inoue M, et al. (2013) Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion. Gut 62: 1347-1355. Available: http://www.ncbi.nlm.nih.gov/pubmed/23242209. Accessed 25 August 2014
13. Liu F, Chen L, Yu D-M, Deng L, Chen R, et al. (2011) Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. Gut 60: 1269-1277. Available: http://www.ncbi.nlm.nih.gov/pubmed/21292683. Accessed 25 August 2014
14. Cheng Y, Guindon S, Rodrigo A, Lim SG (2013) Increased viral quasispecies evolution in HBeAg seroconverter patients treated with oral nucleoside therapy. J Hepatol 58: 217-224. Available: http://www.ncbi.nlm.nih.gov/pubmed/23023011. Accessed 29 August 2014
15. Gregori J, Salicrú M, Domingo E, Sanchez A, Esteban JI, et al. (2014) Inference with viral quasispecies diversity indices: clonal and NGS approaches. Bioinformatics 30: 1104-1111. Available: http://www.ncbi.nlm.nih.gov/pubmed/24389655. Accessed 17 July 2014
16. Ram?rez C, Gregori J, Buti M, Tabernero D, Camós S, et al. (2013) A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model. Antiviral Res 98: 273-283. Available: http://www.ncbi.nlm.nih.gov/pubmed/23523552. Accessed 11 August 2013
17. Gregori J, Esteban JI, Cubero M, Garcia-Cehic D, Perales C, et al. (2013) Ultradeep pyrosequencing (UDPS) data treatment to study amplicon HCV minor variants. PLoS One 8: e83361. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3877031&tool=pmcentrez&rendertype=abstract. Accessed 3 April 2014
18. European Association for the Study of the Liver (2012) EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57: 167-185. Available: http://www.ncbi.nlm.nih.gov/pubmed/22436845. Accessed 7 August 2013
19. Torre F, Cramp M, Owsianka A, Dornan E, Marsden H, et al. (2004) Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity. J Med Virol 72: 370-376. Available: http://www.ncbi.nlm.nih.gov/pubmed/14748060. Accessed 29 August 2014
20. Belnap DM, Watts NR, Conway JF, Cheng N, Stahl SJ, et al. (2003) Diversity of core antigen epitopes of hepatitis B virus. Proc Natl Acad Sci U S A 100: 10884-10889. Available: http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=196897&tool=pmcentrez&rendertype=abstract. Accessed 29 August 2014
21. Yousif M, Bell TG, Mudawi H, Glebe D, Kramvis A (2014) Analysis of ultradeep pyrosequencing and cloning based sequencing of the basic core promoter/precore/core region of hepatitis B virus using newly developed bioinformatics tools. PLoS One 9: e95377. Available at http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3989311&tool=pmcentrez&rendertype=abstract. Accessed 29 August 2014
22. Homs M, Jardi R, Buti M, Schaper M, Tabernero D, et al. (2011) HBV core region variability: effect of antiviral treatments on main epitopic regions. Antivir Ther 16: 37-49. Available: http://www.ncbi.nlm.nih.gov/pubmed/21311107. Accessed 13 March 2011
23. Lavocat F, Dény P, Pichoud C, Al Hawajri N, Kitrinos K, et al. (2013) Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. J Hepatol 59: 684-695. Available: http://www.ncbi.nlm.nih.gov/pubmed/23742912. Accessed 29 August 2014
24. Rodriguez-Fr?as F, Tabernero D, Quer J, Esteban JI, Ortega I, et al. (2012) Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One 7: e37874. Available: http://dx.plos.org/10.1371/journal.pone. 0037874. Accessed 23 May 2014
25. Homs M, Buti M, Quer J, Jard? R, Schaper M, et al. (2011) Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genome. Nucleic Acids Res 39: 8457-8471. Available: http://www.nar.oxfordjournals.org/cgi/doi/10. 1093/nar/gkr451. Accessed 3 April 2014
26. Nishijima N, Marusawa H, Ueda Y, Takahashi K, Nasu A, et al. (2012) Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PLoS One 7: e35052. Availabl e : http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=3327662&tool=pmcentrez&rendertype=abstract. Accessed 27 August 2014
27. Solmone M, Vincenti D, Prosperi MCF, Bruselles A, Ippolito G, et al. (2009) Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 83: 1718-1726. Available: http://jvi.asm.org/cgi/content/abstract/83/4/1718. Accessed 28 December 2012
28. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu TF, et al. (2009) Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 199: 1275-1285. Available: http://www.ncbi.nlm.nih.gov/pubmed/19301976. Accessed 30 June 2010
29. Margeridon-Thermet S, Svarovskaia ES, Babrzadeh F, Martin R, Liu TF, et al. (2013) Low-level persistence of drug resistance mutations in hepatitis B virusinfected subjects with a past history of Lamivudine treatment. Antimicrob Agents Chemother 57: 343-349. Available: http://www.ncbi.nlm.nih.gov/pubmed/23114756. Accessed 23 May 2014
30. Chen MT, Billaud J-N, Sä llberg M, Guidotti LG, Chisari FV, et al. (2004) A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci U S A 101: 14913-14918. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=5220 42&tool=pmcentrez&rendertype=abstract. Accessed 29 August 2014
31. Rodriguez-Frias F, Buti M, Jardi R, Cotrina M, Viladomiu L, et al. (1995) Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 22: 1641-1647. Available: http://www.ncbi.nlm.nih.gov/pubmed/7489968. Accessed 29 August 2014
32. Wang H-Y, Chien M-H, Huang H-P, Chang H-C, Wu C-C, et al. (2010) Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol 84: 3454-3463. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2838120&tool=pmcentrez&ren dertype=abstract. Accessed 29 August 2014
33. Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, et al. (2012) Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 143: 963-73.e9. Available: http://www.ncbi.nlm.nih.gov/pubmed/22796241. Accessed 17 July 2014